Fig. 2From: High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisionsThe prognostic value of ETS2 expression in AML patients from TCGA data. a OS and b EFS and c RFS of the entire AML patients (n = 179). d OS and e EFS and f RFS of the AML patients of ETS2 high group (n = 86), ETS2 low group (n = 88), allogeneic HCT group (n = 72) and chemotherapy-only group (n = 100). Allo allogeneic HCT, Chemo chemotherapyBack to article page